Since its first days of existence, the Institut Pasteur de Lille has been a research institute of excellence dedicated to infectious diseases. It has always combined basic aspects of science with potential applications. The first major success was the development of the Bacillus Calmette-Guérin (BCG) by the first Director General of the Institute, Albert Calmette, and his co-worker Camille Guérin. BCG is the most widely used vaccine in the world and is still the only vaccine available against tuberculosis and leprosy.

During the last decades, the research topics of the Institut Pasteur de Lille have evolved in broader research areas, including a strong focus on parasitology, virology, bacteriology and immunology, as well as on the pathogenesis of cancer, cardiovascular and neurodegenerative diseases. For a number of years now, the main research activities have been structured in CNRS or Inserm research units, which are for most of them in close partnership with Lille University.

The teams that constitute the Center for Infection and Immunity of Lille (CIIL) were part in their previous activities (2006-2009) of:

  • Inserm U547, “Schistosomiase, Paludisme et Inflammation”
  • Inserm U629, “Mécanismes Moléculaires de la Pathogénie Bactérienne”
  • Inserm U774, “Biomolécules et Inflammation Pulmonaire”
  • Inserm U801, “Interactions Cellulaires et Moléculaires des bactéries avec l’hôte”
  • CNRS UMR 8161, “Institut de Biologie de Lille”
  • CNRS UMR 8576, “Glycobiologie Structurale et Fonctionnelle”
  • EA2689, “Détresses Respiratoires et Circulatoires”

The teams have decided since June 2007 to participate in this federating project to increase the visibility and excellence of the Infection and Immunity field. They have structured the research into three major fields (i) Biology of the Pathogen; (ii) Strategies of Infection; (iii) Host Responses and Inflammatory Processes.